News | February 07, 2024
IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The company recently received CEP certificate approval for Losartan Potassium by EDQM
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Digital success is contingent on the way a company organizes itself around technology
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
Subscribe To Our Newsletter & Stay Updated
